MATERIALISE NV (MTLS) Form 6-K — Oct 29, 2026
Materialise NV reported Q3 2026 revenue of 67,670 kEUR, up 2.1% year-over-year, driven by 9.7% growth in the Medical segment to 36,542 kEUR. Software and Manufacturing revenues both declined, and operating profit fell to 1,343 kEUR from 2,522 kEUR as R&D spend rose 11.9%. Profitability compressed: gross margin improved to 57.7%, but adjusted EBIT margin fell to 3.7% from 4.4% and adjusted EBITDA slipped to 8,046 kEUR. Manufacturing segment losses narrowed to (257) kEUR from (845) kEUR.
Key figures
- Eps
- 0.02
- Revenue
- 67670000
- Net Income
- 1383000
- Total Debt
- 71056000
- Revenue Yoy
- 2.1%
- Cash Position
- 153529000
- Gross margin
- 57.7% vs 56.8% prior year
- Adjusted ebit
- 2,485 kEUR vs 2,918 kEUR
- Adjusted ebitda
- 8,046 kEUR vs 8,428 kEUR
- Buyback progress
- 1,426,784 shares repurchased for 7,482 kEUR
- Operating profit
- 1,343 kEUR vs 2,522 kEUR prior year
- Free cash flow q3
- 11,419 kEUR
- Net cash position
- 82,473 kEUR vs 70,805 kEUR at Dec 31, 2025
- Nine month revenue
- 204,020 kEUR vs 197,469 kEUR
- Adjusted ebit margin
- 3.7% vs 4.4%
- Nine month net profit
- 6,535 kEUR vs 1,510 kEUR
- Medical segment revenue
- 36,542 kEUR, +9.7% YoY
- Software segment revenue
- 9,864 kEUR vs 10,286 kEUR
- Manufacturing segment revenue
- 21,266 kEUR vs 22,677 kEUR
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.